Quarterly guidance

Quarterly guidance
No quarterly guidance was given.

Annual guidance

Adjusted EPS
$45.60 to $46.40
Revenue growth
6% to 10%
Operating profit growth
12% to 16%
Free cash flow
$4.5 billion to $4.9 billion
Share repurchases
Approximately $5 billion

Outlook

North American Pharmaceutical
Anticipate revenue growth of 5% to 9% and operating profit growth of 14% to 18%.
Oncology & Multispecialty
Anticipate revenue growth of 20% to 24% and operating profit growth of 18% to 22%.
Prescription Technology Solutions
Anticipate revenue growth of 2.5% to 6.5% and operating profit growth of 11% to 15%.
Medical-Surgical Solutions
Anticipate revenue growth of 1% to 6% and operating profit to range from a 4% decline to flat.
Corporate expenses
Anticipate expenses at the high end of the $580 million to $640 million range.
Interest expense
Expect to be in the high end of $380 million to $420 million.
Effective tax rate
Anticipate a full year effective tax rate of 18% to 19%.